Gm-ct-01 (Not yet branded)

Other Medications

US Experimental IV 2 Clinical Trials
Galectin-3

Description

GM-CT-01 is a galactomannan polysaccharide derived from guar gum that functions as a galectin-3 antagonist. In colorectal cancer treatment, it is used in combination with 5-fluorouracil for patients with metastatic disease who have progressed through multiple prior lines of therapy. The compound works by blocking galectin-3, a protein involved in cancer cell adhesion, metastasis, and immune evasion.

Mechanism of Action

GM-CT-01 binds to and inhibits galectin-3, a beta-galacto

Molecular Targets

Side Effects

Fatigue Nausea Diarrhea Abdominal pain Decreased appetite Vomiting Infusion-related reactions Elevated liver enzymes

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT00110721 Phase 2
Archived
GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer
United States, Israel
NCT00054977 Phase 1
Archived
Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors
United States

Quick Info

Brand NameNot yet branded
CategoryOther Medications
US StatusExperimental
AdministrationIV
Clinical Trials2
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
787 trials
Leucovorin
Other Medications
648 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.